FDA Tightens Rules to Block Infections in Donated Tissues
Published Date: 2/3/2025
Notice
Summary
This update helps hospitals and tissue banks keep human cells and tissues safer by reducing the risk of spreading infections like sepsis and tuberculosis. The FDA is changing the deadline for when these safety steps should be put into action, giving everyone a clearer timeline to protect patients. These changes aim to keep people safe without causing big costs or delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Safer HCT/Ps: Sepsis Implementation Timeline
The FDA revised its guidance on human cells, tissues, and cellular and tissue-based products (HCT/Ps) to change the time by which it recommends hospitals and tissue banks put in place steps to reduce the risk of sepsis. You (as a patient) should see safer handling of HCT/Ps aimed at protecting patients, and the FDA says it intends these changes to avoid big costs or delays for providers.
Safer HCT/Ps: TB Implementation Timeline
The FDA revised its guidance on human cells, tissues, and cellular and tissue-based products (HCT/Ps) to change the time by which it recommends implementation of steps to reduce the risk of transmitting Mycobacterium tuberculosis (Mtb). This aims to make HCT/Ps safer for patients while seeking to avoid large costs or delays for hospitals and tissue banks.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-02154, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Labeling Requirements for Prescription Drugs
The FDA is asking for approval to collect info about how prescription drug labels are made and used. This affects drug makers who must follow clear rules to keep labels easy to understand and safe. The goal? Make sure labels help people use medicines right without extra costs or delays.
Next: 2025-02168, Agency Information Collection Activities: Submission for OMB Review; Comment Request
CMS wants your thoughts on their plan to collect info from the public again. This is a chance to share how much time or effort it might take and suggest ways to make it easier. If you’re involved with Medicare or Medicaid, your input helps shape how this info is gathered, with no new costs or deadlines yet.